Raoom trading Company (TADAWUL:4144)

CTI BioPharma Income Statement

Financials in millions SAR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	107.79	116.04	135.04	135.23	110.19	108.86
Revenue Growth (YoY)	-14.70%	-14.07%	-0.14%	22.72%	1.23%	12.63%
Cost of Revenue	77.31	78.98	92.47	91.52	72.2	69.49
Gross Profit	30.48	37.06	42.57	43.71	38	39.36
Selling, General & Admin	14.03	13.48	11.79	10.24	10.47	10.22
Operating Expenses	14.06	13.5	11.83	9.63	10.47	10.42
Operating Income	16.43	23.56	30.73	34.08	27.52	28.94
Interest Expense	-1.22	-1.16	-1.21	-1.32	-1.23	-1.26
Interest & Investment Income	1.18	1.1	1.08	-	-	-
Currency Exchange Gain (Loss)	0.06	0.06	0.11	-	-	-
Other Non Operating Income (Expenses)	-2.85	-1.23	-	0	0.2	-
EBT Excluding Unusual Items	13.59	22.33	30.72	32.76	26.49	27.68
Gain (Loss) on Sale of Investments	6.03	23.81	18.37	-0.47	-	-
Gain (Loss) on Sale of Assets	0.14	0.14	0.14	0.07	-0	-
Pretax Income	19.75	46.28	49.23	32.36	26.49	27.68
Income Tax Expense	2.92	3.42	2.66	1.62	1.61	1.61
Net Income	16.83	42.86	46.58	30.74	24.88	26.07
Net Income to Common	16.83	42.86	46.58	30.74	24.88	26.07
Net Income Growth	-64.34%	-7.99%	51.50%	23.55%	-4.54%	52.93%
Shares Outstanding (Basic)	13	13	13	13	13	13
Shares Outstanding (Diluted)	13	13	13	13	13	13
Shares Change (YoY)	1.06%	-	-	-	-	-56.59%
EPS (Basic)	1.33	3.43	3.73	2.46	1.99	2.09
EPS (Diluted)	1.33	3.43	3.73	2.46	1.99	2.08
EPS Growth	-64.71%	-7.99%	51.50%	23.55%	-4.48%	252.03%
Free Cash Flow	12.52	21.57	32.43	46.65	17.03	34.45
Free Cash Flow Per Share	0.99	1.73	2.59	3.73	1.36	2.76
Dividend Per Share	1.500	1.500	1.250	1.500	0.500	-
Dividend Growth	140.00%	20.00%	-16.67%	200.00%	-	-
Gross Margin	28.28%	31.94%	31.52%	32.32%	34.48%	36.16%
Operating Margin	15.24%	20.31%	22.76%	25.20%	24.98%	26.59%
Profit Margin	15.61%	36.93%	34.49%	22.73%	22.58%	23.95%
Free Cash Flow Margin	11.62%	18.59%	24.01%	34.50%	15.46%	31.65%
EBITDA	20.17	27.11	34.24	37.55	31.11	35.1
EBITDA Margin	18.71%	23.36%	25.36%	27.77%	28.24%	32.24%
D&A For EBITDA	3.75	3.55	3.5	3.47	3.59	6.15
EBIT	16.43	23.56	30.73	34.08	27.52	28.94
EBIT Margin	15.24%	20.31%	22.76%	25.20%	24.98%	26.59%
Effective Tax Rate	14.79%	7.40%	5.40%	5.00%	6.07%	5.82%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.